Prophylactic and therapeutic treatment of skin sensitization and irritation

• US 5,912,010 A
• Filed: 07/21/1997
• Issued: 06/15/1999
• Est. Priority Date: 11/22/1994
• Status: Expired due to Fees

• Current Assignee: Convatec Incorporated (ConvaTec Group Plc)
• Original Assignee: ER Squibb & Sons LLC (Bristol-Myers Squibb Company)
• Inventors: Kydonieus, Agis, Wille, John J.
• Primary Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US08/897,905
• Time in Patent Office: 694 Days
• Field of Search: 424/449, 424/422, 424/451, 424/464, 514/922
• US Class Current: 424/449
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/75 Anti-irritant
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61K 8/365 Hydroxycarboxylic acids; Ketocarboxylic acids
• CPC Class Codes: A61K 8/4946 Imidazoles or their condensed derivatives, e.g. benzimidazoles
• CPC Class Codes: A61K 8/63 Steroids; Derivatives thereof
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61Q 17/00 Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Abstract

Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

Claims

1. A method of preventing or treating an adverse reaction of the skin of a warm-blooded animal to the presence of at least one of a skin-sensitizing agent or a skin-irritating agent comprising administering, by non-cutaneous routes, to said warm-blooded animal an amount of an adverse skin reaction preventing or treating agent sufficient to prevent or treat said adverse reaction without achieving a systemically active concentration, said adverse skin reaction preventing or treating agent comprising at least one loop diuretic alone or in combination with at least one mast cell degranulator or glucocorticosteroid.

2. The method of claim 1 wherein the skin-sensitizing agent is selected from the group consisting of therapeutic agents, metals, fragrances, cosmetics, textiles, pollen, pesticides, plastics and combinations thereof.

3. The method of claim 1 wherein the skin-irritating agent is selected from the group consisting of water, cleansers, alkalis, acids, oils, organic solvents, oxidizing agents, reducing agents and combinations thereof.

4. The method of claim 1 wherein the loop diuretic is selected from the group consisting of ethacrynic acid, furosemide and bumetanide.

5. The method of claim 4, wherein the loop diuretic is ethacrynic acid.

6. The method of claim 1 wherein the mast cell degranulator is selected from the group consisting of cis-urocanic acid, 1 -furanacrylic acid, 2-pyrole acrylic acid. 2-thiophenacrylic acid, dihydrourocanic acid, trans-urocanic acid, histamine, N¹ -methylhistamine, N¹ -methyl histidine, histidine, imidazolepyruvic acid, N³ -methylhistidine, imidazoleacetic acid, hydantoin 5-propionic acid, imidazolonepropionic acid, psoralen treated with ultraviolet radiation, chloroquine, histamine, capsaicin, morphine sulfate, a sodium channel ionophore, a calcium channel ionophore, an inhibitor of Na+/K+ channel ATPase, quinine, 4-amino pyridine, anti-human IgE antibody, compound 48/80, substance P, estradiol, somatastatin, carbachol, progesterone, spantide, and clonidine.

7. The method of claim 1 wherein the analogs of cis-urocanic acid are selected from the group consisting of 1-furanacrylic acid, 2-pyrole acrylic acid, 2-thiophenacrylic acid, dihydrourocanic acid and trans-urocanic acid.

8. The method of claim 6 wherein the mast cell degranulator is cis-urocanic acid.

9. The method of claim 1 wherein the glucocorticosteroid is selected from the group consisting of hydrocortisone, beclomethasone, betamethasone, clobetasol, desonide, dexamethasone, fluocinonide, prednisone, and triamcinolone.

10. The method of claim 9 wherein the glucocorticosteroid is hydrocortisone.